Navigation Links
PDL BioPharma to Announce Third Quarter 2013 Financial Results on November 6, 2013
Date:10/28/2013

INCLINE VILLAGE, Nev., Oct. 28, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its third quarter 2013 financial results for the period ended September 30, 2013, on Wednesday, November 6, 2013, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results.  A slide presentation relating to the call will be available via the webcast link on the PDL website.

(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

Conference Call Details

To access the live conference call via phone, please dial (800) 668-4132 from the United States and Canada or (224) 357-2196 internationally. The conference ID is 93070209. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through November 12, 2013, and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 93070209.

To access the live and subsequently archived webcast of the conference call, go to the Company's website at http://www.pdl.com and go to "Events & Presentations." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharma

PDL BioPharma manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies. PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it receives significant royalty revenue. PDL is currently focused on intellectual property asset management, investing in new income generating assets, and maximizing value for its shareholders.

The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL was founded in 1986 and is headquartered in Incline Village, Nevada.

In 2011, PDL initiated a strategy to bring in new income generating assets from the healthcare sector. To accomplish this goal, PDL seeks to provide non-dilutive growth capital and financing solutions to late stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL successfully executed on this strategy by deploying over $125 million in 2012 and continues to pursue this strategic initiative. PDL is focused on the quality of the income generating assets and potential returns on investment. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
2. Bright Future Ahead for Biopharmaceutical Contract Manufacturing, Says Frost & Sullivan
3. Enteris BioPharma and Nordic BioSciences KeyBioScience Enter Strategic Licensing Agreement to Develop Metabolic Peptides Using Enteris Proprietary Oral Drug Delivery and Manufacturing Platform
4. CDISC and TransCelerate BioPharma Inc. Announce Landmark Asthma Data Standard Released for Public Review
5. Benu BioVentures to Finance Early Biopharmaceutical Clinical Development
6. Therapure Biopharma Inc. wins a 2013 CMO Leadership Award in All 5 Categories: Quality, Reliability, Innovation, Productivity and Regulatory
7. Recently Patented Technology Poised To Disrupt The Plasma Biopharmaceutical Market
8. Life Cycle Management of Biopharmaceuticals, New Life Science Webinar Hosted by Xtalks
9. KBI Biopharma Selects Freeslate’s Biologics Formulation System for Early and Late Stage Drug Development
10. 6th BSMA Annual Executive Summit to Address the Supply Chain Challenges and Solutions of Biopharma
11. Before the Bell Scans: Hologic Inc., St. Jude Medical Inc., ResMed Inc., and Navidea Biopharmaceuticals Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... ... enable the world’s most progressive pharma and biotech organizations to do more clinical ... pharma and biotech events in Q4. , DrugDev will demonstrate DrugDev Spark™, the ...
(Date:9/20/2017)... ... September 20, 2017 , ... The award-winning ... Services (Koch) to feature new innovations aimed at helping farmers solve the problem ... American Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your local listings for ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... study examining the effects of exoskeleton-assisted walking on gait parameters and neuromuscular ... article, "Neuromechanical adaptations during a robotic powered exoskeleton assisted walking session" (doi:10.1080.10790268.2017.1314900) ...
(Date:9/19/2017)... ... , ... Participants of this educational webinar will learn the ... the advantages and disadvantages of ductless, filtered fume hoods, they will also discover ... Attendees will learn from an industry expert about the different types of ducted ...
Breaking Biology Technology:
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):